This supplement to The American Journal of Managed Care reviews the pathophysiology of postherpetic neuralgia (PHN) and strategies for the prevention of PHN. The treatment of PHN is also discussed, including limitations of current treatments, and unmet need in the treatment of PHN.This supplement was supported by Depomed Inc.
Gerald M. Sacks, MD
Director of Pain Management
Pain Institute of Santa Monica
Santa Monica, California
Gerald M. Sacks, MD, reports relationships with the following organizations:
Consultancies or paid advisory boards/honoraria/lecture fees/meeting or conference attendance: Depomed Inc; Endo Pharmaceuticals; Janssen Pharmaceuticals, Inc; Pfizer; Purdue
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.